Olema Oncology Fuels Breast Cancer Pipeline with $190M Offering
- $190M: Olema Oncology raises $190 million in a public offering.
- 10M shares: Offering consists of 10,000,000 shares priced at $19.00 per share.
- 2 Phase 3 Trials: Palazestrant is being evaluated in OPERA-01 and OPERA-02 for advanced breast cancer.
Experts view the funding as a strong vote of confidence in Olema’s pipeline, particularly palazestrant’s potential to overcome resistance in advanced breast cancer treatments.
Olema Oncology Fuels Breast Cancer Pipeline with $190M Offering
NEW YORK, NY – November 19, 2025
Olema Oncology, a clinical-stage biopharmaceutical company focused on breast cancer treatment, today announced the pricing of a $190.0 million public offering. The offering of 10,000,000 shares of common stock, priced at $19.00 per share, provides a significant capital injection for the company as it advances its pipeline of novel therapies targeting estrogen receptor-positive (ER+) and HER2-negative breast cancer.
Funding a Promising Pipeline
The substantial funding round underscores investor confidence in Olema’s strategy and the potential of its lead candidate, palazestrant. Palazestrant is an orally available complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), designed to overcome resistance mechanisms commonly seen with existing endocrine therapies. Currently, palazestrant is being evaluated in two Phase 3 clinical trials – OPERA-01 and OPERA-02 – addressing critical unmet needs in both later-line and first-line treatment settings for advanced breast cancer.
“The financing provides Olema with the resources to accelerate clinical development and potentially bring a much-needed innovation to patients battling advanced breast cancer,” explained one industry analyst. “Palazestrant’s unique mechanism of action as a CERAN and SERD sets it apart, offering the potential to overcome resistance to current therapies.